INTERACTION OF PERSPECTIVE ANTIDEPRESSANT WITH NOOTROPIC PROPERTIES 2-METHYL-3-PHENYLAMINOMETHYLQUINOLIN-4-ONE WITH CNS STIMULANTS AND DEPRESSANTS
https://doi.org/10.21886/2219-8075-2014-1-80-84
Abstract
Purpose. To research possible interactions of 2-methyl-3-phenylaminomethylquinolin-4-one (3-AMQ) with CNS stimulants and depressants.Materials and methods. The interaction of the said substance with strychnine and thiosemicarbazide was studied on the seizure models, with caffeine - in the open field test, with CNS depressants (sodium thiopental, ethanol) - measuring duration of the anesthetic sleep.Results. The trend of attenuation of strychnine and thiosemicarbazide convulsive action was revealed on seizure models for 3-AMQ. In the open field test 3-AMQ leveled the anxiogenic effects of caffeine that was reflected in the exploratory activity increase. The trend of elongation of narcosis induction time (up to 18%) and reduction of narcosis duration (up to 17%) was found in the model using thiopental-induced anesthesia. In the ethanol-induced narcosis 3-AMQ reduced the duration of animals’ anesthetic sleep by 19.2% (p<0.05).Summary. The absence of pro-convulsive properties and potentiating interactions with barbiturates was proved for 3-AMQ. Beneficial modulating influence on effects of caffeine was revealed. The alcoprotective activity of 3-AMQ was proved.

About the Authors
I. N. PodolskyRussian Federation
Medicinal chemistry department
S. Yu. Shtrygol
Russian Federation
Pharmacology department
V. A. Zubkov
Russian Federation
Medicinal chemistry department
I. S. Gritsenko
Russian Federation
Medicinal chemistry department
References
1. World Health Organization. World Health Statistics 2012/Geneva: WHO, 2012. -176 p.
2. Scharzberg A.F. Manual of clinical psychopharmacology: 7th edition/A.F. Scharzberg, J.O. Cole, C. DeBattista. -American Psychiatric Publishing, Inc., 2010. -P. 37-168.
3. 2-Метил-3-фениламинометилхинолин-4-он -потенциальный антидепрессант с ноотропными свойствами/С.Ю. Штрыголь, В.А. Зубков, И.Н. Подольский, И.С. Гриценко//Экспериментальная и клиническая фармакология. -2012. -Т. 75, № 4. -С. 7-9.
4. Патент України №70698 на корисну модель. Застосування 2-метил-3-фенiламiнометилхiнолiн-4-ону як засобу антигiпоксичної, актопротекторної та антиалкогольної дiї/С.Ю. Штриголь, I.М. Подольський, В.О. Зубков, I.С. Гриценко. -№ u201113573; заявл. 18.11.11; опубл. 25.06.12, Бюл. № 12.
5. Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ/Под общ. ред. Р.У. Хабриева. -[2-е изд., перераб. и доп.]. -М.: ОАО «Издательство «Медицина», 2005. -832 с.
6. Раевский К.С. Нейрохимические аспекты фармакологии ГАМК-ергических веществ/К.С. Раевский//Фармакол. и токсикол. -1981. -№ 5. -С. 517-528.
7. Машковский М.Д. Лекарственные средства. -15-е изд., перераб., испр. и доп. -М.: ООО «Издательство Новая Волна», 2005. -1200 с.
8. Штрыголь С.Ю. Модуляция фармакологических эффектов при различных солевых режимах: [монография]. -Х.: Ависта ВЛТ, 2007. -360 с.
9. Буреш Я. Методики и основные эксперименты по изучению мозга и поведения/Я. Буреш, О. Бурешова, Д.П. Хьюстон. -М.: Высшая школа, 1991. -С. 119-122.
10. Jackson M.J. Depression and anxiety in epilepsy/M.J. Jackson, D. Turkington//Journal of Neurology, Neurosurgery and Psychiatry. -2005. -Vol. 76, suppl. 1. -i45-i47.
11. The anxiogenic-like effect of caffeine in two experimental procedures measuring anxiety in the mouse is not shared by selective A(2A) adenosine receptor antagonists/M. El Yacoubi, C. Ledent, M. Parmentier et al.//Psychopharmacology. -2000. -Vol. 148, № 2. -P. 2153-2163.
Review
For citations:
Podolsky I.N., Shtrygol S.Yu., Zubkov V.A., Gritsenko I.S. INTERACTION OF PERSPECTIVE ANTIDEPRESSANT WITH NOOTROPIC PROPERTIES 2-METHYL-3-PHENYLAMINOMETHYLQUINOLIN-4-ONE WITH CNS STIMULANTS AND DEPRESSANTS. Medical Herald of the South of Russia. 2014;(1):80-84. (In Russ.) https://doi.org/10.21886/2219-8075-2014-1-80-84